Shinhung Co., Ltd (KRX:004080)
13,730
-30 (-0.22%)
At close: Oct 31, 2025
Shinhung Revenue
Shinhung had revenue of 24.54B KRW in the quarter ending June 30, 2025, a decrease of -1.76%. This brings the company's revenue in the last twelve months to 98.68B, down -8.15% year-over-year. In the year 2024, Shinhung had annual revenue of 101.76B, down -9.50%.
Revenue (ttm)
98.68B
Revenue Growth
-8.15%
P/S Ratio
1.30
Revenue / Employee
493.41M
Employees
200
Market Cap
128.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 101.76B | -10.69B | -9.50% |
| Dec 31, 2023 | 112.44B | -5.73B | -4.85% |
| Dec 31, 2022 | 118.18B | -8.68B | -6.84% |
| Dec 31, 2021 | 126.85B | 10.20B | 8.74% |
| Dec 31, 2020 | 116.65B | -6.36B | -5.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |